Cytyc’s InDuct
This article was originally published in The Gray Sheet
Executive Summary
CareFirst BlueCross BlueShield positive coverage decision for the ductal lavage procedure will provide reimbursement for 3.1 mil. members in Northern Virginia, Washington D.C., Maryland and Delaware. The decision follows Empire BlueCross BlueShield positive coverage policy and further mitigates the firm's concern that reimbursement could be an obstacle to increased adoption of the breast cancer risk assessment tool (1"The Gray Sheet" Jan. 28, 2002, p. 13)...
You may also be interested in...
Cytyc Eyes InDuct Expanded Coverage, Product Indications
Empire BlueCross BlueShield's positive coverage policy for Cytyc's InDuct ductal lavage device has mitigated the firm's concern that reimbursement could be an obstacle to increased adoption of the breast cancer risk assessment tool
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.